Maged Shenouda, CFO at RELMADA THERAPEUTICS, INC. (RLMD), sold 19,900 shares at $35.11 ($706K) on 2021-03-10, disclosed to the SEC on 2021-03-10.
Open-market sale of $706k RLMD by CFO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.00 | 100 | $4K | 0.5% |
| 2 | $35.42 | 5,727 | $203K | 28.8% |
| 3 | $35.42 | 5,727 | $203K | 28.8% |
| 4 | $36.02 | 1,800 | $65K | 9.2% |
| 5 | $36.02 | 1,800 | $65K | 9.2% |
| 6 | $35.11 | 2,373 |
| $83K |
| 11.8% |
| 7 | $35.11 | 2,373 | $83K | 11.8% |
| Total | $35.45 avg | 19,900 | $706K | 100% |
| Filing → |
| RLMD | BUY | 2025-11-06 | $1.1M | — | Filing → |
| RLMD | BUY | 2025-05-20 | $97K | — | Filing → |
| RLMD | BUY | 2024-09-11 | $207K | — | Filing → |